US equities |
SPCX $167.56 ▲+5.41% NVDA $237.18 ▲+1.38% MU $1,067.75 ▼-0.66% TSLA $376.37 ▲+1.56% MSFT $526.24 ▲+1.68% INTC $117.03 ▼-1.93% SNDK $1,725.04 ▲+0.29% META $745.05 ▲+2.33%
FinancialContent

Monte Rosa Therapeutics, Inc. - Common Stock (NQ:GLUE)

10.09 -0.41 (-3.90%)
Delayed Quote Updated: 10:59 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Monte Rosa Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk
Conference call and webcast to be held at 8:00 a.m. ET on Oct. 1, 2026 
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Monte Rosa Therapeutics (NASDAQ:GLUE) Beats Q2 Revenue Estimates but Posts Wider Loss ↗
Via Chartmill
Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Reports Q1 2026 Results as Clinical Progress Drives Focus on Upcoming Catalysts ↗
Via Chartmill
News headline image
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount ↗
Via Stocktwits
News headline image
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
Gapping stocks in Friday's session ↗
Via Chartmill
Friday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale? ↗
This clinical-stage biotech focused on precision medicines reported a notable insider sale amid a year of exceptional share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise ↗
This biotech focused on precision medicines for cancer and immune disorders disclosed a notable insider sale after a strong year for shares. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher ↗
Via MarketBeat
Nasdaq, S&P 500 Futures Pause Ahead Of Jobs Report, Trump Tariff Ruling: Why OPEN, INTC, NVDA, TLRY, CRMD, GLUE Are On Traders' Radar Today ↗
Via Stocktwits
Topics Government Stocks
News headline image
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
From Monte Rosa Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Great Thaw: Biotech Fundraising Surges as Monte Rosa and Genelux Tap Reopening Markets
The biotechnology sector, long frozen in a capital-starved "biology winter," is showing definitive signs of a seasonal shift. On January 7, 2026, the industry witnessed a significant injection of... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
< Previous 1 2 3 4 5 6 7 Next >